Verrica Pharmaceuticals posted $14.3 million in Q3 2025 revenue, primarily from milestone payments and sales of YCANTH. The company recorded a minor net loss of $0.3 million, a notable improvement from the $22.9 million loss in Q3 2024. Operating expenses declined sharply due to cuts in commercial and marketing spending. With $21.1 million in cash on hand, Verrica continues advancing late-stage programs, including global Phase 3 trials for YCANTH and VP-315.